The risk of transmitting prion disease by blood or plasma products

Transfusion and Apheresis Science

Volumn 43, Issue 3, 2010, Pages 387-391

  Knight, Richard ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE;

ARTICLE; BLOOD; BLOOD DONOR; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; BLOODSTREAM INFECTION; BOVINE SPONGIFORM ENCEPHALOPATHY; CREUTZFELDT JAKOB DISEASE; DISEASE PREDISPOSITION; DISEASE TRANSMISSION; DONOR SELECTION; ERYTHROCYTE; HUMAN; PLASMA; PRION DISEASE; RISK ASSESSMENT;

ANIMALS; BLOOD SAFETY; BLOOD TRANSFUSION; CATTLE; CREUTZFELDT-JAKOB SYNDROME; DISEASE TRANSMISSION, INFECTIOUS; ENCEPHALOPATHY, BOVINE SPONGIFORM; ERYTHROCYTES; FACTOR VIII; HUMANS; LEUKOCYTES; PLASMA EXCHANGE; PRION DISEASES; RISK;

EID: 78649477663     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2010.09.003     Document Type: Article

References (30)

1. Bruce M.E., Will R.G., Ironside J.W., et al. Transmission to mice indicates that new variant CJD is caused by the BSE agent. Nature 1997, 389:498-501.
2. Collinge J., Sidle K.C.L., Meads J., Ironside J., Hill A.F. Molecular analysis of prion strain variation and the aetiology of " new variant" CJD. Nature 1996, 383:685-690.
3. Knight R. The relationship between new variant Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. Vox Sang 1999, 76:203-208.
4. Llewelyn C.A., Hewitt P.A., Knight R.S.G., et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004, 363:417-421.
5. Wroe S.J., Pal S., Siddique D., et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 2006, 368:2061-2067.
6. Health Protection Agency Fourth case of transfusion-associated variant-CJD. Health Protect Report 2007, 1(3).
7. Peden A.H., Head M.W., Ritchie D.L., Bell J.E., Ironside J.W. Preclinical vCJD after blood transfusion in a PRNP 129 heterozygous patient. Lancet 2004, 364:527-529.
8. Hewitt P.E., Llewelyn C.A., Mackenzie J., Will R.G. Creutzfeldt-Jakob disease and blood transfusion: results of the UK transfusion. Medicine epidemiological review study. Vox Sang 2006, 91:221-230.
9. Peden A., McCardle L., Head M.W., Love S., Ward H.J.T., Cousens S.N., et al. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010, 16:296-304.
10. Brown P. Creutzfeldt-Jakob disease: reflections on the risk from blood product therapy. Haemophilia 2007, 13(Suppl. 5):32-39.
11. Ludlam C.A., Turner M.C. Managing the risk of transmission of variant CJD by blood products. Br J Haematol 2006, 132:13-24.
12. Ward H.J.T., MacKenzie J.M., Llewelyn C.A., Knight R.S.G., Hewitt P.E., Connor N., et al. Variant Creutzfeldt-Jakob disease and exposure to fractionated plasma products. Vox Sang 2009, 97:207-210.
13. Prusiner S.B. Prion biology and diseases 2004, 1-87. Cold Spring Harbour Laboratory Press, New York. S.B. Prusiner (Ed.).
14. Brown P. Transmissible spongiform encephalopathy in the 21st century. Neuroscience for the clinical neurologist. Neurology 2008, 70:713-722.
15. Hilton D.A., Ghani A., Conyers L., et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004, 203:733-739.
16. Bishop M.T., Hart P., Aitchison L., Baybutt H.N., Plinston C., Thomson V., et al. Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol 2006, 5:393-398.
17. Clarke P., Ghani A.C. Projections of the future course of the primary vCJD epidemic in the UK: inclusion of subclinical infection and the possibility of wider genetic susceptibility. J Royal Soc Interf 2005, 2:19-31.
18. Brown P., Rohwer R.G., Dunstan B.C., MacAuley C., Gajdusek D.C., Drohan W.N. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 1998, 38:810-816.
19. Brown P., Cervenáková L., McShane L.M., Barber P., Rubenstein R., Drohan W.N. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999, 39:1169-1178.
20. Cervenáková L. Infectivity in blood of experimental mice: vCJD update. Cambridge Healthtech Institute 8th Annual Meeting 2002 " Transmissible Spongiform Encephalopathy's" , Washington, DC.
21. Det Norske Veritas. Risk of infection from variant CJD in blood; 2004. [accessed 16.10.09]. http://www.dnv.com/news_events/news/2004/riskofinfectionfromvariantcjdinblood.asp.
22. Houston F., Foster J.D., Chong A., Hunter N., Bostock C.J. Transmission of BSE by blood transfusion in sheep. Lancet 2000, 356:999-1000.
23. Hunter N., Foster J., Chong A., McCutcheon S., Parnham D., Eaton S., et al. Transmission of prion diseases by blood transfusion. J Gen Virol 2002, 83:2897-2905.
24. Houston F., McCutcheon S., Goldmann W., et al. Prion diseases are efficiently transmitted by blood transfusion in sheep. Blood 2008, 112:4739-4745.
25. Gregori L., McCombie N., Palmer D., et al. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Lancet 2004, 364:529-531.
26. Clewley J.P., Kelly C.M., Andrews N., et al. Prevalence of disease related prion protein in anonymous tonsil specimens in Britain: a cross sectional opportunistic survey. BMJ 2009, 338:b1442.
27. Spongiform Encephalopathy Advisory Committee. Position statement: prevalence of subclinical variant Creutzfeldt-Jakob disease infections; 2008. [accessed 16.10.09]. http://www.seac.gov.uk/statements/state-cjd-infections.pdf.
28. Nurmi M.H., Bishop M., Strain L., Brett F., McGuigan C., Hutchison M., et al. The normal population distribution of PRPN codon 129 polymorphism. Acta Scand Neurol 2003, 108:374.
29. Kaski D., Mead S., Hyare H., Cooper S., Jampana R., Overell J., et al. Lancet 2009, 374:2128.
30. Gregori L., Gurgel P.V., Lathrop J.T., et al. Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins. Lancet 2006, 368:2226-2230.